» Articles » PMID: 11302812

Enhanced Expression of the Multidrug Efflux Pumps AcrAB and AcrEF Associated with Insertion Element Transposition in Escherichia Coli Mutants Selected with a Fluoroquinolone

Overview
Specialty Pharmacology
Date 2001 Apr 17
PMID 11302812
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

The development of fluoroquinolone resistance in Escherichia coli may be associated with mutations in regulatory gene loci such as marRAB that lead to increased multidrug efflux, presumably through activation of expression of the AcrAB multidrug efflux pump. We found that multidrug-resistant (MDR) phenotypes with enhanced efflux can also be selected by fluoroquinolones from marRAB- or acrAB-inactivated E. coli K-12 strains having a single mutation in the quinolone-resistance-determining region of gyrA. Mutant 3-AG100MKX, obtained from a mar knockout strain after two selection steps, showed enhanced expression of acrB in a reverse transcriptase PCR associated with insertion of IS186 into the AcrAB repressor gene acrR. In vitro selection experiments with acrAB knockout strains yielded MDR mutants after a single step. Enhanced efflux in these mutants was due to increased expression of acrEF and associated with insertion of IS2 into the upstream region of acrEF, presumably creating a hybrid promoter. These observations confirm the importance of efflux-associated nontarget gene mutations and indicate that transposition of genetic elements may have a role in the development of fluoroquinolone resistance in E. coli.

Citing Articles

Transcriptional mechanism by which IS5 activates the fucAO operon in Escherichia coli.

Zhou H, Zhang Z, Velo J, Huo J, Smith S, Ho A Nucleic Acids Res. 2025; 53(5).

PMID: 40066878 PMC: 11894529. DOI: 10.1093/nar/gkaf172.


A genome-to-proteome atlas charts natural variants controlling proteome diversity and forecasts their fitness effects.

Jakobson C, Hartl J, Trebulle P, Mulleder M, Jarosz D, Ralser M bioRxiv. 2024; .

PMID: 39484408 PMC: 11526991. DOI: 10.1101/2024.10.18.619054.


A metagenomics pipeline reveals insertion sequence-driven evolution of the microbiota.

Kirsch J, Hryckowian A, Duerkop B Cell Host Microbe. 2024; 32(5):739-754.e4.

PMID: 38565143 PMC: 11081829. DOI: 10.1016/j.chom.2024.03.005.


A metagenomics pipeline reveals insertion sequence-driven evolution of the microbiota.

Kirsch J, Hryckowian A, Duerkop B bioRxiv. 2023; .

PMID: 37873088 PMC: 10592638. DOI: 10.1101/2023.10.06.561241.


Transiently silent acquired antimicrobial resistance: an emerging challenge in susceptibility testing.

Wagner T, Howden B, Sundsfjord A, Hegstad K J Antimicrob Chemother. 2023; 78(3):586-598.

PMID: 36719135 PMC: 9978586. DOI: 10.1093/jac/dkad024.


References
1.
Piddock L . Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs. 1999; 58 Suppl 2:11-8. DOI: 10.2165/00003495-199958002-00003. View

2.
White D, Goldman J, Demple B, Levy S . Role of the acrAB locus in organic solvent tolerance mediated by expression of marA, soxS, or robA in Escherichia coli. J Bacteriol. 1997; 179(19):6122-6. PMC: 179517. DOI: 10.1128/jb.179.19.6122-6126.1997. View

3.
Oethinger M, Kern W, Jellen-Ritter A, McMurry L, Levy S . Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother. 1999; 44(1):10-3. PMC: 89620. DOI: 10.1128/AAC.44.1.10-13.2000. View

4.
Jalal S, Ciofu O, Hoiby N, Gotoh N, Wretlind B . Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 2000; 44(3):710-2. PMC: 89751. DOI: 10.1128/AAC.44.3.710-712.2000. View

5.
Kern W, Oethinger M, Jellen-Ritter A, Levy S . Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother. 2000; 44(4):814-20. PMC: 89776. DOI: 10.1128/AAC.44.4.814-820.2000. View